<DOC>
	<DOCNO>NCT03093025</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , efficacy TS-121 adjunctive treatment patient major depressive disorder inadequate response current antidepressant Treatment ( SSRI SNRI ) .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy TS-121 Adjunctive Treatment Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Adult male females 18 65 year age inclusive ( time initial informed consent ) 2 . Patients current diagnosis MDD DSM5 , confirm structure interview use MINI 3 . Patients receive antidepressant ( SSRI SNRI monotherapy ) least 6 week continuous treatment least 4 week fix dose 4 . Patients willing remain primary SSRI SNRI fix dose throughout course study 5 . Patients meet total score HAMD list 1 . HAMD ≥ 21 Screening 2 . HAMD ≤ 25 % improvement Placebo Leadin period 3 . HAMD ≥ 18 End Placebo Leadin period 6 . Body Mass Index ( BMI ) ≥ 18 ≤ 35 kg/m2 1 . Patients inadequate response ≥2 prior antidepressant treatment ( include current antidepressant ) least 4 week duration current episode 2 . Patients whose current depressive episode diagnose psychotic feature , catatonic feature , postpartum ( primary onset ) , secondary general medical disorder 3 . Patients diagnosis follow DSM5 class disorder 1 . Schizophrenia spectrum psychotic disorder 2 . Bipolar relate disorder 3 . Anxiety disorder 4 . Obsessivecompulsive related disorder 5 . Trauma Stressorrelated disorder 4 . Patients receive electroconvulsive therapy ( ECT ) within 12 month Screening , receive one course ECT lifetime plan receive ECT study 5 . Patients receive repetitive transcranial magnetic stimulation ( rTMS ) within 12 month Screening plan receive rTMS study 6 . Patients plan initiate terminate cognitive behavioral psychotherapy alter frequency ongoing therapy study 7 . Patients attempt suicide within past 6 month 8 . Patients history presence intellectual disability , pervasive developmental disorder , cognitive disorder , neurodegenerative disorder , brain injury 9 . Patients history complication convulsive disorder 10 . Patients undergoing treatment psychotropic medication , benzodiazepine , metyrapone , lithium and/or corticosteroid 11 . Patients take moderate strong CYP3A4 inhibitors/inducers</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Adjunctive Treatment</keyword>
</DOC>